These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 27000240)

  • 21. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
    Zwibel HL;
    Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment.
    Guillemin GJ; Kerr SJ; Pemberton LA; Smith DG; Smythe GA; Armati PJ; Brew BJ
    J Interferon Cytokine Res; 2001 Dec; 21(12):1097-101. PubMed ID: 11798468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 27. Autoimmune hemolytic anemia during interferon-beta-I b treatment for multiple sclerosis.
    Alanoglu G; Kilbas S; Arslan C; Senol A; Kutluhan S
    Mult Scler; 2007 Jun; 13(5):683-5. PubMed ID: 17548453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does interferon beta therapy affect survival of multiple sclerosis patients?
    Kułakowska A; Drozdowski W
    Neurol Neurochir Pol; 2014; 48(6):436-41. PubMed ID: 25482255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis.
    Leppert D; Waubant E; Bürk MR; Oksenberg JR; Hauser SL
    Ann Neurol; 1996 Dec; 40(6):846-52. PubMed ID: 9007089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
    Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
    J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 35. [Interferon beta-1b now also for the secondary progressive form of multiple sclerosis?].
    de Haan RJ; Vermeulen M
    Ned Tijdschr Geneeskd; 1999 Apr; 143(14):709-11. PubMed ID: 10347623
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacoeconomic modeling of drug therapies for multiple sclerosis--are we building houses on sand?
    Curtiss FR
    J Manag Care Pharm; 2007 Apr; 13(3):287-9. PubMed ID: 17407397
    [No Abstract]   [Full Text] [Related]  

  • 37. [The role of interferon beta in the treatment of multiple sclerosis].
    Seeldrayers P
    Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of multiple sclerosis with interferon beta 1b.
    Dhib-Jalbut S; McFarland HF
    Baillieres Clin Neurol; 1997 Oct; 6(3):467-80. PubMed ID: 10101584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations.
    Bagnato F; Gupta S; Richert ND; Stone RD; Ohayon JM; Frank JA; McFarland HF
    Arch Neurol; 2005 Nov; 62(11):1684-8. PubMed ID: 16157739
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous vasculitis associated with interferon beta-1b treatment for multiple sclerosis.
    Szilasiová J; Gdovinová Z; Jautová J; Baloghová J; Ficová M; Bohus P
    Clin Neuropharmacol; 2009; 32(5):301-3. PubMed ID: 19820436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.